Dramatic Response to First Line Single Agent Pembrolizumab in Anaplastic Thyroid Carcinoma
Anaplastic thyroid carcinoma (ATC) is a deadly disease with very limited therapeutic options. There is an urgent need for new and efficacious drugs. Unfortunately accrual in clinical trials is problematic because of the rarity of the disease and often poor performance status at diagnosis. Recently s...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Case Reports in Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2019/9095753 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850174435634446336 |
|---|---|
| author | Valérie Spalart Barbara Legius Kurt Segers Johan Coolen Brigitte Maes Lynn Decoster |
| author_facet | Valérie Spalart Barbara Legius Kurt Segers Johan Coolen Brigitte Maes Lynn Decoster |
| author_sort | Valérie Spalart |
| collection | DOAJ |
| description | Anaplastic thyroid carcinoma (ATC) is a deadly disease with very limited therapeutic options. There is an urgent need for new and efficacious drugs. Unfortunately accrual in clinical trials is problematic because of the rarity of the disease and often poor performance status at diagnosis. Recently some data have emerged suggesting a role for immunotherapy in the treatment of ATC. We describe the case of a 75-year-old patient with poor performance status and compromised airway and oesophagus at diagnosis, showing a rapid and dramatic response to first line single agent pembrolizumab. Disease progression in the brain occurred 16 months after initial diagnosis. At that time there was ongoing extracranial disease control. |
| format | Article |
| id | doaj-art-d64ae34827044df2aba2f247ac1ea79b |
| institution | OA Journals |
| issn | 2090-6501 2090-651X |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Endocrinology |
| spelling | doaj-art-d64ae34827044df2aba2f247ac1ea79b2025-08-20T02:19:40ZengWileyCase Reports in Endocrinology2090-65012090-651X2019-01-01201910.1155/2019/90957539095753Dramatic Response to First Line Single Agent Pembrolizumab in Anaplastic Thyroid CarcinomaValérie Spalart0Barbara Legius1Kurt Segers2Johan Coolen3Brigitte Maes4Lynn Decoster5AZ Turnhout, Department of Internal Medicine, Turnhout, BelgiumAZ Turnhout, Department of Pulmonology/Respiratory Oncology, Turnhout, BelgiumAZ Turnhout, Department of Pathology, Turnhout, BelgiumUniversity Hospitals Leuven, Department of Radiology, Leuven, BelgiumJessa Hospital Hasselt, Laboratory for Molecular Diagnostics, Department of Clinical Biology, Hasselt, BelgiumAZ Turnhout, Department of Pulmonology/Respiratory Oncology, Turnhout, BelgiumAnaplastic thyroid carcinoma (ATC) is a deadly disease with very limited therapeutic options. There is an urgent need for new and efficacious drugs. Unfortunately accrual in clinical trials is problematic because of the rarity of the disease and often poor performance status at diagnosis. Recently some data have emerged suggesting a role for immunotherapy in the treatment of ATC. We describe the case of a 75-year-old patient with poor performance status and compromised airway and oesophagus at diagnosis, showing a rapid and dramatic response to first line single agent pembrolizumab. Disease progression in the brain occurred 16 months after initial diagnosis. At that time there was ongoing extracranial disease control.http://dx.doi.org/10.1155/2019/9095753 |
| spellingShingle | Valérie Spalart Barbara Legius Kurt Segers Johan Coolen Brigitte Maes Lynn Decoster Dramatic Response to First Line Single Agent Pembrolizumab in Anaplastic Thyroid Carcinoma Case Reports in Endocrinology |
| title | Dramatic Response to First Line Single Agent Pembrolizumab in Anaplastic Thyroid Carcinoma |
| title_full | Dramatic Response to First Line Single Agent Pembrolizumab in Anaplastic Thyroid Carcinoma |
| title_fullStr | Dramatic Response to First Line Single Agent Pembrolizumab in Anaplastic Thyroid Carcinoma |
| title_full_unstemmed | Dramatic Response to First Line Single Agent Pembrolizumab in Anaplastic Thyroid Carcinoma |
| title_short | Dramatic Response to First Line Single Agent Pembrolizumab in Anaplastic Thyroid Carcinoma |
| title_sort | dramatic response to first line single agent pembrolizumab in anaplastic thyroid carcinoma |
| url | http://dx.doi.org/10.1155/2019/9095753 |
| work_keys_str_mv | AT valeriespalart dramaticresponsetofirstlinesingleagentpembrolizumabinanaplasticthyroidcarcinoma AT barbaralegius dramaticresponsetofirstlinesingleagentpembrolizumabinanaplasticthyroidcarcinoma AT kurtsegers dramaticresponsetofirstlinesingleagentpembrolizumabinanaplasticthyroidcarcinoma AT johancoolen dramaticresponsetofirstlinesingleagentpembrolizumabinanaplasticthyroidcarcinoma AT brigittemaes dramaticresponsetofirstlinesingleagentpembrolizumabinanaplasticthyroidcarcinoma AT lynndecoster dramaticresponsetofirstlinesingleagentpembrolizumabinanaplasticthyroidcarcinoma |